Expertise in
5
conditions

Michael W. Ronellenfitsch

Dr. Senckenberg Institute Of Neurooncology, 
Frankfurt Am Main, HE, DE 
Expertise in
5
conditions
Dr. Senckenberg Institute Of Neurooncology, 
Frankfurt Am Main, HE, DE 

Overview

Michael Ronellenfitsch practices practicing medicine in Frankfurt Am Main, Germany.

Mr. Ronellenfitsch is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Gliomatosis Cerebri.

He is actively involved in clinical research, co-authoring 87 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Dr. Senckenberg Institute Of Neurooncology, Frankfurt Am Main, HE, Germany
Other Locations
Marburg An Der Lahn, HE, Germany
Heidelberg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Characterization of Metabolic Changes in the Glioma Tumor Tissue Induced by Transient Fasting (ERGO3)
Characterization of Metabolic Changes in the Glioma Tumor Tissue Induced by Transient Fasting (ERGO3)
Enrollment Status: Active_not_recruiting
Publish Date: October 17, 2024
Intervention Type: Other
Study Phase: Not Applicable
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Procedure
View 1 Less Clinical Trial

87 Total Publications

Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY).
Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY).
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 30, 2026

Frequently Asked Questions about Michael W. Ronellenfitsch

Is Michael W. Ronellenfitsch a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Michael W. Ronellenfitsch is classified as an Distinguished expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Michael W. Ronellenfitsch participate in research or clinical trials?

Yes. Michael W. Ronellenfitsch has published 87 articles and abstracts on conditions like Glioma. You can view a list of Michael W. Ronellenfitsch's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ronellenfitsch's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile